Significant Improvement in Gross Margin
GAAP and non-GAAP gross margin for the first quarter of 2025 was 46%, significantly higher than the 32% GAAP and 34% non-GAAP gross margin reported for the first quarter of 2024.
Substantial Decrease in Operating Expenses
First quarter 2025 GAAP operating expense was $11.4 million, a 66% decrease compared to $33.9 million in the first quarter of 2024. Non-GAAP operating expense was $8.5 million, compared to $24.4 million in the prior year.
Increase in Installed Base of OGM Systems
The installed base of OGM systems grew to 379, which is a 9% year-over-year increase.
Successful Strategic Shift
The company executed a strategic shift focusing on existing users with the potential to be routine users of Bionano's products.
Strong Academic and Clinical Publications
The first quarter of 2025 had 95 publications, second only to the 99 publications in the first quarter of 2024. Notably, MD Anderson Cancer Center published a study highlighting the utility of optical genome mapping.